
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CK-0045
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cytoki Pharma Doses First Patient in Phase 2 Trial of CK-0045 for Obesity and Diabetes
Details : CK-0045 is a long-acting analogue of interleukin-22 (IL-22), an atypical, non-immunomodulatory cytokine that selectively targets epithelial cells, is being evaluated for obesity & type 2 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2024
Lead Product(s) : CK-0045
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CK-0045
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Profil Institut für Stoffwechselforschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes
Details : CK-0045 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2024
Lead Product(s) : CK-0045
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Profil Institut für Stoffwechselforschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CK-0045
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cytoki Pharma Announces Positive Phase 1 Data for CK-0045 in Cardiometabolic Risk Factors
Details : CK-0045 is a long-acting analogue of interleukin-22 (IL-22), an atypical, non-immunomodulatory cytokine that selectively targets epithelial cells, is being evaluated for obesity & type 2 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 23, 2024
Lead Product(s) : CK-0045
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CK-0045
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : SGS Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CK-0045 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2023
Lead Product(s) : CK-0045
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : SGS Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
